Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Effect of oral CBD on objective and subjective sleep outcomes in people with COPD: an open-label clinical pilot study.
FY 2021-22
Summary
Chronic obstructive pulmonary disease (COPD) affects 17% of Canadians
aged 40 years and older. More than 50% of people with COPD suffer from
abnormally low sleep quality (SQ). Effective management of abnormally
low SQ in people with COPD is a challenge and requires novel
therapeutic solutions. Following legalization of cannabis in Canada in
2018, cannabidiol (CBD), the safe and non-psychoactive component of
the Cannabis sativa plant, has received increased attention for its
potential medicinal properties. Evidence suggests that CBD may improve
SQ in healthy adults and people with sleep abnormalities. However, the
effects of CBD therapy on SQ in people with COPD is unknown and
represents the focus of our research. We hypothesize that CBD therapy
will be associated with improved SQ in people with COPD, without
significant adverse side effects. Twenty-four adults (12 males, 12
females) aged ≥40 years with clinically stable COPD will be recruited.
Following a one-week baseline control period (pre-CBD), participants
will be randomized in a 1:1 ratio to receive either 3 or 6 mg/kg of
body mass/day of CBD isolate for a period of four weeks, where CBD
will be given by mouth with participants aware that they are receiving
CBD (i.e., open-label). Objective SQ outcomes (e.g., total sleep time,
sleep efficiency, number of awakenings) will be recorded by an
actigraphy watch each evening during baseline and treatment periods.
Subjective SQ will be evaluated using the Pittsburg Sleep Quality
Index on days 3 and 7 of the baseline period, and days 7, 14, 21 and
28 of the four-week treatment period. Anticipated results would
support the feasibility and provide preliminary evidence on the
efficacy of oral CBD in the management of sleep disturbance in COPD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
481145
Name
Girard Felix M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effect of oral CBD on objective and subjective sleep outcomes in people with COPD: an open-label clinical pilot study.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Actigraphy; Cannabidiol; Chronic Obstructive Pulmonary Disease; Pittsburgh Sleep Quality Index (Psqi) Questionnaire; Sleep
Abstract
<html>
<head>
</head>
<body>
<div class="margin-bottom-xlarge" align="start" style="margin-bottom: 0; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">
<div class="span-8 print-textarea-font wordBreak" style="float: left; margin-left: 0; margin-right: 0; width: 1180px; white-space: normal !important; margin-bottom: 20px">
Chronic obstructive pulmonary disease (COPD) affects 17% of Canadians
aged 40 years and older. More than 50% of people with COPD suffer from
abnormally low sleep quality (SQ). Effective management of abnormally
low SQ in people with COPD is a challenge and requires novel
therapeutic solutions. Following legalization of cannabis in Canada in
2018, cannabidiol (CBD), the safe and non-psychoactive component of
the Cannabis sativa plant, has received increased attention for its
potential medicinal properties. Evidence suggests that CBD may improve
SQ in healthy adults and people with sleep abnormalities. However, the
effects of CBD therapy on SQ in people with COPD is unknown and
represents the focus of our research. We hypothesize that CBD therapy
will be associated with improved SQ in people with COPD, without
significant adverse side effects. Twenty-four adults (12 males, 12
females) aged ≥40 years with clinically stable COPD will be recruited.
Following a one-week baseline control period (pre-CBD), participants
will be randomized in a 1:1 ratio to receive either 3 or 6 mg/kg of
body mass/day of CBD isolate for a period of four weeks, where CBD
will be given by mouth with participants aware that they are receiving
CBD (i.e., open-label). Objective SQ outcomes (e.g., total sleep time,
sleep efficiency, number of awakenings) will be recorded by an
actigraphy watch each evening during baseline and treatment periods.
Subjective SQ will be evaluated using the Pittsburg Sleep Quality
Index on days 3 and 7 of the baseline period, and days 7, 14, 21 and
28 of the four-week treatment period. Anticipated results would
support the feasibility and provide preliminary evidence on the
efficacy of oral CBD in the management of sleep disturbance in COPD.
</div>
</div>
<div class="clear" align="start" style="clear: both; display: block; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; width: 0px; height: 0px; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">
</div>
<div class="clear" align="start" style="clear: both; display: block; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; width: 0px; height: 0px; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">
</div>
<div id="cphMainContent_ResearchActivity_updResearchActivity" align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">
<br class="Apple-interchange-newline">
</div>
</body>
</html>
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Girard, Felix M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~